IL-1β induces urokinse- plasminogen activator expression and cell migration through PKCα, JNK1/2, and NF-κB in A549 cells

Journal of Cellular Physiology

Volumn 219, Issue 1, 2009, Pages 183-193

  Cheng, Ching Yi ^a   Hsieh, Hsi Lung ^b   Sun, Chi Chin ^c   Lin, Chih Chung ^a   Luo, Shue Fen ^a   Yang, Chuen Mao ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; HELENALIN; HETERODIMER; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MUTANT PROTEIN; PROTEIN INHIBITOR; PROTEIN KINASE; PROTEIN KINASE C ALPHA; PROTEIN P50; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; UROKINASE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 9; STRESS ACTIVATED PROTEIN KINASE 1; UROKINASE;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL MEMBRANE; CELL MIGRATION; CELL NUCLEUS; CONCENTRATION RESPONSE; ENZYME ACTIVATION; GENE EXPRESSION; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; ANIMAL; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1BETA; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; NF-KAPPA B; PROTEIN KINASE C-ALPHA; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 60849104423     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21669     Document Type: Article

References (47)

1. Amos S, Mut M, diPierro CG, Carpenter JE, Xiao A, Kohutek ZA, Redpath GT, Zhao Y, Wang J, Shaffrey ME, Hussaini IM. 2007. Protein kinase C-a-mediated regulation of low-density lipoprotein receptor related protein and urokinase increases astrocytoma invasion. Cancer Res 67:10241-10251.
2. Asada M, Yasuda H, Ebihara S, Tomita N, Suzuki S, Sato M, Kubo H, Yamaya M. 2006. Interleukin-1b gene polymorphisms associated with risk of lung cancer in Japanese. Lung Cancer 54:261-263.
3. Asehnoune K, Strassheim D, Mitra S, Yeol KJ, Abraham E. 2005. Involvement of PKCa/b in TLR4 and TLR2 dependent activation of NF-kB. Cell Signal 17:385-394.
4. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686.
5. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J. 2005. Plasminogen activation and cancer. Thromb Haemost 93:676-681.
6. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. 2008. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122-136.
7. Davis GE, Pintar Allen KA, Salazar R, Maxwell SA. 2001. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 114:917-930.
8. De CD, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. 1995. Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer. Oncogene 11:365-376.
9. De VF, Orditura M, Auriemma A, Infusino S, Catalano G. 1998. Serum concentrations of proinflammatory cytokines in advanced non-small cell lung cancer patients. J Exp Clin Cancer Res 17:413-417.
10. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
11. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR. 2007. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 31:441-449.
12. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, ChengAL. 2008. NF-kB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochem Biophys Res Commun 376:283-287.
13. Gueders MM, Foidart JM, Noel A, Cataldo DD. 2006. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: Potential implications in asthma and other lung diseases. Eur J Pharmacol 533:133-144.
14. Hasegawa T, Sorensen L, Dohi M, Rao NV, Hoidal JR, Marshall BC. 1997. Induction of urokinase-type plasminogen activator receptor by IL-1 beta. Am J Respir Cell Mol Biol 16:683-692.
15. Hsieh HL, Wang HH, Wu CY, Jou MJ, Yen MH, Parker P, Yang CM. 2007. BK-induced COX-2 expression via PKC-delta-dependent activation of p42/p44 MAPK and NF-kappaB in astrocytes. Cell Signal 19:330-340.
16. Huang WC, Chen JJ, Inoue H, Chen CC. 2003. Tyrosine phosphorylation of I-kB kinase a/b by protein kinase C-dependent c-Src activation is involved in TNF-a-induced cyclooxygenase-2 expression. J Immunol 170:4767-4775.
17. Kamio N, Hashizume H, Nakao S, Matsushima K, Sugiya H. 2008. IL-1beta stimulates urokinase-type plasminogen activator expression and secretion in human dental pulp cells. Biomed Res 28:315-322.
18. Karin M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486.
19. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. 2007. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 121:2307-2316.
20. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. 2005. Interleukin-1beta causes pulmonaryinflammation,emphysema, and airwayremodelingin the adult murine lung.Am J Respir Cell Mol Biol 32:311-318.
21. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH. 2003. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63:4648-4655.
22. Legrand C, Polette M, Tournier JM, de BS, Huet E, Monteau M, Birembaut P. 2001. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. Exp Cell Res 264:326-336.
23. Liang KC, Lee CW, Lin WN, Lin CC, Wu CB, Luo SF, Yang CM. 2007. Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells. J Cell Physiol 211:759-770.
24. Lin CC, Tseng HW, Hsieh HL, Lee CW, Wu CY, Cheng CY, Yang CM. 2008. Tumor necrosis factor-alpha induces MMP-9 expression via p42/p44 MAPK, JNK, and nuclear factor- kappaB in A549 cells. Toxicol Appl Pharmacol 229:386-398.
25. Lu JP, Sun H, Cao CC, Ou ZL. 2004. Influence of nuclear factor-kappaB decoy transfection on nuclear factor-kappaB activity and vascular endothelial growth factor/urokinase-type plasminogen activator/intercellular cell adhesion molecule-1 level of SKOV3 cells. Zhonghua Fu Chan Ke Za Zhi 39:533-537.
26. Lyss G, Knorre A, Schmidt TJ, Pahl HL, Merfort I. 1998. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem 273:33508-33516.
27. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, Huang S. 2007. Protein kinase C[alpha]- CARMA3 signaling axis links Ras to NF-[kappa]B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 27:1273-1280.
28. Marshall BC, Xu QP, Rao NV, BrownBR, Hoidal JR. 1992. Pulmonary epithelial cell urokinase- type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor- alpha. J Biol Chem 267:11462-11469.
29. Mignatti P, Rifkin DB. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195.
30. Muniyappa H, Das KC. 2008. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and B203580: A MLK-3-MKK7-dependent mechanism. Cell Signal 20:675-683.
31. Niiya K, Shinbo M, Ozawa T, Hayakawa Y, SakuragawaN. 1995. Modulationof urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8. Thromb Haemost 74:1511-1515.
32. OffersenBV, Pfeiffer P, Andreasen P, Overgaard J. 2007. Urokinase plasminogen activatorand plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis. Lung Cancer 56:43-50.
33. Ogura N, Tobe M, Tamaki H, Nagura H, Abiko Y. 2001. IL-1beta increases uPA and uPA receptor expression in human gingival fibroblasts. IUBMB Life 51:381-385.
34. Parra M, Lluis F, Miralles F, Caelles C, Munoz-Canoves P. 2000. The cJun N-terminal kinase (JNK) signaling pathway mediates induction of urokinase-type plasminogen activator (uPA) by the alkylating agent MNNG. Blood 96:1415-1424.
35. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl- Hansen J. 1994. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54:4671-4675.
36. Pepper MS. 2001. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21:1104-1117.
37. Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA, Lakka SS. 2005. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther 4:1399-1408.
38. Reuning U, Guerrini L, Nishiguchi T, Page S, Seibold H, Magdolen V, Graeff H, Schmitt M. 1999. Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. Eur J Biochem 259:143-148.
39. Rømer J. 2003. Skin cancer and wound healing. Tissue-specific similarities in extracellular proteolysis. APMIS 111:1-36.
40. Smith PC, Santibanez JF, Morales JP, Martinez J. 2004. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin. J Periodontal Res 39:380-387.
41. Solomon A, Li DQ, Lee SB, Tseng SCG. 2000. Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci 41:2154-2163.
42. Susarla R, Watkinson JC, Eggo MC. 2007. Regulation of plasminogen activators in human thyroid follicular cells and their relationship to differentiated function. J Cell Physiol 212:643-654.
43. Tran-Thang C, Kruithof E, Lahm H, Schuster WA, Tada M, Sordat B. 1996. Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells. Br J Cancer 74:846-852.
44. Van Leer C, Stutz M, HaeberliA, Geiser T. 2005. Urokinase plasminogenactivatorreleased by alveolar epithelial cells modulates alveolar epithelial repair in vitro. Thromb Haemost 94:1257-1264.
45. Visse R, Nagase H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92:827-839.
46. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC. 2005. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 354:91-99.
47. Yu J, Bian D, Mahanivong C, Cheng RK, Zhou W, Huang S. 2004. p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J Biol Chem 279:50446-50454.